유전성 혈관부종 치료제 시장 보고서(2026년)

Hereditary angioedema (HAE) therapeutics refer to treatments for an autosomal dominant disorder caused by a deficiency or dysfunction of the C1-inhibitor protein. Symptoms of hereditary angioedema include angioedema affecting the upper airway, skin, and/or gastrointestinal tract.

The main drug classes of hereditary angioedema therapeutics include C1 esterase inhibitors, selective bradykinin B2 receptor antagonists, kallikrein inhibitors, and others. C1 esterase inhibitor is a protein found in the fluid component of blood that regulates the complement system protein C1. These therapeutics are administered through intravenous, subcutaneous, and oral routes and are distributed via hospital pharmacies, retail pharmacies, and other channels. Applications of hereditary angioedema therapeutics include both prophylactic treatment and on-demand management.

Tariffs have influenced the hereditary angioedema therapeutics market by increasing the cost of imported biologics and specialty drug components, particularly affecting segments like recombinant C1 esterase inhibitors and kallikrein inhibitors. Regions such as North America and Europe, which import advanced therapies, face higher production and distribution costs. While tariffs have slowed some adoption due to elevated pricing, they have also encouraged local manufacturing and innovation in cost-efficient treatment delivery solutions, creating potential opportunities for domestic players.

The hereditary angioedema therapeutics market research report is one of a series of new reports from The Business Research Company that provides hereditary angioedema therapeutics market statistics, including hereditary angioedema therapeutics industry global market size, regional shares, competitors with a hereditary angioedema therapeutics market share, detailed hereditary angioedema therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the hereditary angioedema therapeutics industry. This hereditary angioedema therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hereditary angioedema therapeutics market size has grown rapidly in recent years. It will grow from $7.77 billion in 2025 to $9.27 billion in 2026 at a compound annual growth rate (CAGR) of 19.3%. The growth in the historic period can be attributed to limited awareness about hae, dependency on hospital-based therapy, fewer approved therapeutic options, reliance on intravenous administration, low prevalence diagnosis rates.

The hereditary angioedema therapeutics market size is expected to see rapid growth in the next few years. It will grow to $19.03 billion in 2030 at a compound annual growth rate (CAGR) of 19.7%. The growth in the forecast period can be attributed to growth in recombinant c1 esterase inhibitors, adoption of subcutaneous delivery methods, rising prophylactic therapy usage, expansion of specialty pharmacy channels, increasing investment in rare disease research. Major trends in the forecast period include personalized therapy development, increased orphan drug approvals, advancements in subcutaneous drug delivery, development of on-demand treatment options, expansion of hospital and retail pharmacy networks.

The rising level of healthcare expenditure is anticipated to drive the expansion of the hereditary angioedema therapeutics market in the coming years. Healthcare expenditure represents the total financial and resource-based spending on healthcare goods and services within a defined period and geographic region. Higher healthcare spending enables greater investment in research and development initiatives aimed at understanding the underlying mechanisms of hereditary angioedema and advancing innovative therapeutic options. For example, in June 2025, according to the Centers for Medicare & Medicaid Services, a US-based federal agency, National Health Expenditure increased by 7.5% to $4.9 trillion in 2023, equating to $14,570 per person and accounting for 17.6% of the gross domestic product. Hospital expenditures rose by 10.4% to $1,519.7 billion in 2023, significantly outpacing the 3.2% growth recorded in 2022. As a result, increasing healthcare expenditure is supporting the growth of the hereditary angioedema therapeutics market.

Major companies operating in the hereditary angioedema therapeutics market are focusing on the development of innovative treatment options, such as oral plasma kallikrein inhibitors, to improve disease management and offer effective, on-demand solutions for controlling hereditary angioedema attacks. Oral plasma kallikrein inhibitors are orally administered drugs that block the activity of the plasma kallikrein enzyme, thereby reducing the severity and frequency of hereditary angioedema episodes. For instance, in September 2024, KalVista Pharmaceuticals, a US-based biopharmaceutical company, received acceptance from the U.S. Food and Drug Administration for a new drug application for sebetralstat. This therapy is intended to provide patients with a convenient, non-invasive alternative to intravenous or subcutaneous treatments, addressing the growing need for fast-acting oral therapies that can be administered immediately during an attack.

In February 2023, Takeda Pharmaceutical Company, a Japan-based pharmaceutical company, acquired Nimbus Lakshmi Inc. from Nimbus Therapeutics LLC for an undisclosed amount. This acquisition strengthened Takeda's late-stage development pipeline and supported the expansion of its portfolio across multiple therapeutic areas, helping to sustain long-term global growth. Nimbus Lakshmi Inc., a wholly owned subsidiary of Nimbus Therapeutics, is a US-based company developing the tyrosine kinase 2 inhibitor NDI-034858.

Major companies operating in the hereditary angioedema therapeutics market are Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., Dyax Corp., Pharvaris N.V., Kedrion Biopharma Inc., Shire Pharmaceuticals, Octapharma AG, Pharmalink AB, Sobi AB, OctoPharma USA, HAE Pharma, Argenx SE, ImmunoGen Inc., Ionis Pharmaceuticals (for pipeline HAE therapies), PharmAthene Inc., BioMarin Pharmaceutical Inc.

North America was the largest region in the global hereditary angioedema therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the hereditary angioedema therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hereditary angioedema therapeutics market includes revenues earned by entities by diagnosis and evaluation, treatment, and management of hereditary angioedema. The market value includes the value of related goods sold by the service provider or included within the service offering. The hereditary angioedema therapeutics market also includes of sales of tranexamic acid, danazol, intravenous and subcutaneous nano-filtered purified plasma-derived human C1 esterase inhibitor concentrate, and lanadelumab. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hereditary Angioedema Therapeutics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses hereditary angioedema therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hereditary angioedema therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hereditary angioedema therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Class: C1 Esterase Inhibitor; Selective Bradykinin B2 Receptor Antagonist; Kallikrein Inhibitor; Other Drug Classes
• 2) By Route of Administration: Intravenous; Subcutaneous; Oral
• 3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Other Distribution Channels
• 4) By Application: Prophylaxis; On-Demand
• Companies Mentioned: Sanofi S.A.; Pharming Healthcare Inc.; Attune Pharmaceuticals Inc.; BioCryst Pharmaceuticals Inc.; CSL Behring LLC; KalVista Pharmaceutical Inc.; Dyax Corp.; Pharvaris N.V.; Kedrion Biopharma Inc.; Shire Pharmaceuticals; Octapharma AG; Pharmalink AB; Sobi AB; OctoPharma USA; HAE Pharma; Argenx SE; ImmunoGen Inc.; Ionis Pharmaceuticals (for pipeline HAE therapies); PharmAthene Inc.; BioMarin Pharmaceutical Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Hereditary Angioedema Therapeutics Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Hereditary Angioedema Therapeutics Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Hereditary Angioedema Therapeutics Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Hereditary Angioedema Therapeutics Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Artificial Intelligence & Autonomous Intelligence
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Personalized Therapy Development
  • 4.2.2 Increased Orphan Drug Approvals
  • 4.2.3 Advancements In Subcutaneous Drug Delivery
  • 4.2.4 Development Of On-Demand Treatment Options
  • 4.2.5 Expansion Of Hospital And Retail Pharmacy Networks

5. Hereditary Angioedema Therapeutics Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Specialty Clinics
• 5.3 Retail Pharmacies
• 5.4 Home Healthcare Providers
• 5.5 Oncology And Rare Disease Centers

6. Hereditary Angioedema Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Hereditary Angioedema Therapeutics Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Hereditary Angioedema Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Hereditary Angioedema Therapeutics Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Hereditary Angioedema Therapeutics Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Hereditary Angioedema Therapeutics Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Hereditary Angioedema Therapeutics Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Hereditary Angioedema Therapeutics Market Segmentation

• 9.1. Global Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes
• 9.2. Global Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Intravenous, Subcutaneous, Oral
• 9.3. Global Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
• 9.4. Global Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Prophylaxis, On-Demand
• 9.5. Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of C1 Esterase Inhibitor, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• C1 Esterase Inhibitor Therapies
• 9.6. Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of Selective Bradykinin B2 Receptor Antagonist, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Selective Bradykinin B2 Receptor Antagonist Therapies
• 9.7. Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of Kallikrein Inhibitor, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Kallikrein Inhibitor Therapies
• 9.8. Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Other HAE Drug Classes

10. Hereditary Angioedema Therapeutics Market Regional And Country Analysis

• 10.1. Global Hereditary Angioedema Therapeutics Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Hereditary Angioedema Therapeutics Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Hereditary Angioedema Therapeutics Market

• 11.1. Asia-Pacific Hereditary Angioedema Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Hereditary Angioedema Therapeutics Market

• 12.1. China Hereditary Angioedema Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Hereditary Angioedema Therapeutics Market

• 13.1. India Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Hereditary Angioedema Therapeutics Market

• 14.1. Japan Hereditary Angioedema Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Hereditary Angioedema Therapeutics Market

• 15.1. Australia Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Hereditary Angioedema Therapeutics Market

• 16.1. Indonesia Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Hereditary Angioedema Therapeutics Market

• 17.1. South Korea Hereditary Angioedema Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Hereditary Angioedema Therapeutics Market

• 18.1. Taiwan Hereditary Angioedema Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Hereditary Angioedema Therapeutics Market

• 19.1. South East Asia Hereditary Angioedema Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Hereditary Angioedema Therapeutics Market

• 20.1. Western Europe Hereditary Angioedema Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Hereditary Angioedema Therapeutics Market

• 21.1. UK Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Hereditary Angioedema Therapeutics Market

• 22.1. Germany Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Hereditary Angioedema Therapeutics Market

• 23.1. France Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Hereditary Angioedema Therapeutics Market

• 24.1. Italy Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Hereditary Angioedema Therapeutics Market

• 25.1. Spain Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Hereditary Angioedema Therapeutics Market

• 26.1. Eastern Europe Hereditary Angioedema Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Hereditary Angioedema Therapeutics Market

• 27.1. Russia Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Hereditary Angioedema Therapeutics Market

• 28.1. North America Hereditary Angioedema Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Hereditary Angioedema Therapeutics Market

• 29.1. USA Hereditary Angioedema Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Hereditary Angioedema Therapeutics Market

• 30.1. Canada Hereditary Angioedema Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Hereditary Angioedema Therapeutics Market

• 31.1. South America Hereditary Angioedema Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Hereditary Angioedema Therapeutics Market

• 32.1. Brazil Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Hereditary Angioedema Therapeutics Market

• 33.1. Middle East Hereditary Angioedema Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Hereditary Angioedema Therapeutics Market

• 34.1. Africa Hereditary Angioedema Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Hereditary Angioedema Therapeutics Market Regulatory and Investment Landscape

36. Hereditary Angioedema Therapeutics Market Competitive Landscape And Company Profiles

• 36.1. Hereditary Angioedema Therapeutics Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Hereditary Angioedema Therapeutics Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Hereditary Angioedema Therapeutics Market Company Profiles
  • 36.3.1. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Pharming Healthcare Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Attune Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. BioCryst Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. CSL Behring LLC Overview, Products and Services, Strategy and Financial Analysis

37. Hereditary Angioedema Therapeutics Market Other Major And Innovative Companies

• KalVista Pharmaceutical Inc., Dyax Corp., Pharvaris N.V., Kedrion Biopharma Inc., Shire Pharmaceuticals, Octapharma AG, Pharmalink AB, Sobi AB, OctoPharma USA, HAE Pharma, Argenx SE, ImmunoGen Inc., Ionis Pharmaceuticals, PharmAthene Inc., BioMarin Pharmaceutical Inc.

38. Global Hereditary Angioedema Therapeutics Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Hereditary Angioedema Therapeutics Market

40. Hereditary Angioedema Therapeutics Market High Potential Countries, Segments and Strategies

• 40.1 Hereditary Angioedema Therapeutics Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Hereditary Angioedema Therapeutics Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Hereditary Angioedema Therapeutics Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer